You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
McKinsey
McKesson
Boehringer Ingelheim
Harvard Business School

Last Updated: May 10, 2021

DrugPatentWatch Database Preview

Celator Pharms Company Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Celator Pharms
International Patents:116
US Patents:9
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Celator Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Celator Pharms VYXEOS cytarabine; daunorubicin POWDER;INTRAVENOUS 209401-001 Aug 3, 2017 RX Yes Yes 10,028,912   Get Started for $10 Y   Get Started for $10
Celator Pharms VYXEOS cytarabine; daunorubicin POWDER;INTRAVENOUS 209401-001 Aug 3, 2017 RX Yes Yes 7,850,990   Get Started for $10 Y   Get Started for $10
Celator Pharms VYXEOS cytarabine; daunorubicin POWDER;INTRAVENOUS 209401-001 Aug 3, 2017 RX Yes Yes 10,835,492   Get Started for $10   Get Started for $10
Celator Pharms VYXEOS cytarabine; daunorubicin POWDER;INTRAVENOUS 209401-001 Aug 3, 2017 RX Yes Yes 8,092,828   Get Started for $10   Get Started for $10
Celator Pharms VYXEOS cytarabine; daunorubicin POWDER;INTRAVENOUS 209401-001 Aug 3, 2017 RX Yes Yes 8,518,437   Get Started for $10 Y   Get Started for $10
Celator Pharms VYXEOS cytarabine; daunorubicin POWDER;INTRAVENOUS 209401-001 Aug 3, 2017 RX Yes Yes 9,271,931   Get Started for $10 Y   Get Started for $10
Celator Pharms VYXEOS cytarabine; daunorubicin POWDER;INTRAVENOUS 209401-001 Aug 3, 2017 RX Yes Yes 10,166,184   Get Started for $10 Y   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for Celator Pharms Drugs

Country Patent Number Estimated Expiration
Spain 2272768   Get Started for $10
European Patent Office 2120568   Get Started for $10
Taiwan I329025   Get Started for $10
Portugal 1744764   Get Started for $10
Australia 2002340670   Get Started for $10
European Patent Office 1432402   Get Started for $10
Japan 2017160211   Get Started for $10
>Country >Patent Number >Estimated Expiration

Supplementary Protection Certificates for Celator Pharms Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2768484 2019C/545 Belgium   Get Started for $10 PRODUCT NAME: COMBINATIE VAN DAUNORUBICINE EN CYTARABINE; AUTHORISATION NUMBER AND DATE: EU/1/18/1308 20180827
2768484 2019041 Norway   Get Started for $10 PRODUCT NAME: KOMBINASJON AV DAUNORUBICIN OG CYTARABIN; REG. NO/DATE: EU/1/18/1308 20180831
2768484 53/2019 Austria   Get Started for $10 PRODUCT NAME: KOMBINATION VON DAUNORUBICIN UND CYTARABIN; REGISTRATION NO/DATE: EU/1/18/1308 (MITTEILUNG) 20180827
2768484 2019/054 Ireland   Get Started for $10 PRODUCT NAME: COMBINATION OF DAUNORUBICIN AND CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180827
2768484 C201930069 Spain   Get Started for $10 PRODUCT NAME: COMBINACION DE DAUNORUBICINA Y CITARABINA; NATIONAL AUTHORISATION NUMBER: EU/1/18/1308; DATE OF AUTHORISATION: 20180823; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1308; DATE OF FIRST AUTHORISATION IN EEA: 20180823
1744764 C201830057 Spain   Get Started for $10 PRODUCT NAME: DAUNORUBICINA + CITARABINA; NATIONAL AUTHORISATION NUMBER: EU/1/18/1308; DATE OF AUTHORISATION: 20180823; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1308; DATE OF FIRST AUTHORISATION IN EEA: 20180823
2768484 19C1063 France   Get Started for $10 PRODUCT NAME: COMBINAISON DE DAUNORUBICINE ET CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180827
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Moodys
Baxter
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.